Allspring Global Investments Holdings LLC Sells 34,332 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Allspring Global Investments Holdings LLC decreased its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 12.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 245,139 shares of the biotechnology company’s stock after selling 34,332 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in ADMA Biologics were worth $1,108,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of ADMA. Charles Schwab Investment Management Inc. lifted its position in ADMA Biologics by 182.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,609,346 shares of the biotechnology company’s stock worth $5,761,000 after buying an additional 1,039,893 shares during the last quarter. Walleye Capital LLC bought a new stake in ADMA Biologics in the 3rd quarter worth approximately $3,318,000. American Century Companies Inc. lifted its position in ADMA Biologics by 20.8% in the 3rd quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock worth $17,514,000 after buying an additional 840,761 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in ADMA Biologics by 15.1% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 3,767,558 shares of the biotechnology company’s stock worth $13,488,000 after buying an additional 493,000 shares during the last quarter. Finally, Invesco Ltd. lifted its position in ADMA Biologics by 8.5% in the 3rd quarter. Invesco Ltd. now owns 5,417,166 shares of the biotechnology company’s stock worth $19,393,000 after buying an additional 426,446 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $6.54 on Wednesday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.69 and a current ratio of 5.16. ADMA Biologics, Inc. has a fifty-two week low of $3.06 and a fifty-two week high of $6.76. The stock has a 50 day moving average price of $6.00 and a two-hundred day moving average price of $4.82. The company has a market capitalization of $1.49 billion, a P/E ratio of -50.31 and a beta of 0.46.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. The firm had revenue of $73.90 million during the quarter, compared to the consensus estimate of $73.50 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. Analysts expect that ADMA Biologics, Inc. will post 0.3 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on ADMA. Cantor Fitzgerald boosted their price objective on ADMA Biologics from $6.50 to $8.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Mizuho boosted their price objective on ADMA Biologics from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.50 price objective (up previously from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, ADMA Biologics presently has an average rating of “Buy” and a consensus price target of $7.88.

Insider Activity at ADMA Biologics

In related news, Director Steve Elms sold 183,008 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $6.01, for a total transaction of $1,099,878.08. Following the completion of the transaction, the director now owns 2,577,387 shares in the company, valued at $15,490,095.87. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 639,895 shares of company stock worth $3,927,169 over the last quarter. 5.90% of the stock is owned by corporate insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.